Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
20-23 October, 2025
62nd Japanese Peptide62nd Japanese Peptide
Not Confirmed
Not Confirmed
21-23 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
20-23 October, 2025
62nd Japanese Peptide62nd Japanese Peptide
Industry Trade Show
Not Confirmed
21-23 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india
14 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-completes-acquisition-of-theravia-302529332.html
09 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/swissmedic-approves-ifinwil-eflornithine-for-children-diagnosed-with-high-risk-neuroblastoma-hrnb-302499271.html
17 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-welcomes-tga-registration-in-australia-of-ifinwil-eflornithine-for-adults-and-children-diagnosed-with-high-risk-neuroblastoma-hrnb1-302430883.html
15 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/norgine-strengthens-rare-disease-portfolio-with-acquisition-of-theravia-302427963.html
24 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/x4-pharmaceuticals-announces-ema-validation-of-marketing-authorization-application-maa-for-mavorixafor---licenced-to-norgine-for-commercialisation-in-europe-302359812.html
13 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/13/3008383/0/en/X4-Pharmaceuticals-and-Norgine-Enter-into-Exclusive-Licensing-Agreement-to-Commercialize-Mavorixafor-in-Europe-Australia-and-New-Zealand.html
ABOUT THIS PAGE